Select a city Select a city

Lornolyof - Lornolyof Lyophilized Powder for Intramuscular and Intravenous Injection 8mg 10 pcs

#108320_969
 0 (0 review)
Characteristics
Status
Select a city
Find it at the pharmacyPharmacies
BrandRompharm / Rompharm
Brand country Romania
Quantity and shape10 vials
Genericslornoxicam
Short description
Short-term symptomatic treatment of acute mild to moderate pain in adults.
81.00₾
1
Package
Select a city
To generate delivery methods
Similar products
  • Description
  • Reviews

Lornoliof

Trade name of the drug: Lornoliof

Active substance (INN): Lornoxicam

Dosage form: Powder and solvent for solution for injection.

Composition:

1 vial of powder contains:

Active substance: Lornoxicam 8 mg

Excipients: Mannitol (E421), trometamol, disodium edetate.

1 ampoule with 2 ml of solvent contains: Water for injection.

Description: The powder is a sterile, yellow compacted mass/powder. The solvent is a sterile, clear and colorless solution, practically free from visible particles. The reconstituted solution is a sterile, yellow, clear solution. The reconstituted solution has an osmolarity of 360mOsm/kg. pH of the reconstituted solution: 8.0 -9.3.

Therapeutic preparation category: Anti-inflammatory and antirheumatic products, non-steroids, oxicams.

ATC code: M01AC05

Pharmacological properties

Pharmacodynamics

Mechanism of action

Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. The mode of action of lornoxicam is mainly related to the inhibition of prostaglandin synthesis (inhibition of the cyclooxygenase enzyme), which leads to the desensitization of peripheral nociceptors and, consequently, the inhibition of inflammation. A central effect on nociceptors is also suggested, which does not seem to be dependent on the anti-inflammatory effect.

Pharmacodynamic effects

Lornoxicam does not affect vital signs (e.g., body temperature, respiratory rate, heart rate, blood pressure, ECG, spirometry).

Clinical efficacy and safety

The analgesic properties of lornoxicam have been successfully demonstrated in several clinical trials during the development of the drug.

Due to local gastrointestinal irritation and systemic ulcerogenic effects associated with the inhibition of prostaglandin (PG) synthesis, gastrointestinal complications are frequent adverse effects following treatment with lornoxicam, as is the case with other NSAIDs.

Pharmacokinetic properties

Absorption

Lornoxicam 8 mg powder for injection is intended for intravenous (i.v.) and also intramuscular (i.m.) administration. After i.m. injection, maximum plasma concentration is reached after approximately 0.4 hours. Absolute bioavailability (calculated on AUC) after intramuscular administration is 97%.

Distribution

Lornoxicam is found in plasma in unchanged form and as a hydroxylated metabolite. Plasma protein binding of lornoxicam is 99% and is not concentration-dependent. It is also found in synovial fluid after repeated dosing.

Biotransformation

Lornoxicam is extensively metabolized in the liver, primarily to inactive 5-hydroxylornoxicam via hydroxylation. CYP2C9 is involved in the biotransformation of lornoxicam. Due to genetic polymorphism, there are slow and extensive metabolizers for this enzyme, which can lead to noticeably increased plasma levels of lornoxicam in slow metabolizers. The hydroxylated metabolite shows no pharmacological activity. Lornoxicam is completely metabolized and approximately 2/3 is excreted via the liver and 1/3 via the kidneys as an inactive substance.

In animal models, lornoxicam did not induce liver enzymes. Within the clinical trial data, there is no evidence of lornoxicam accumulation after repeated administration when used according to the recommended dose. This conclusion is supported by drug monitoring data obtained from one-year studies.

Elimination

The mean elimination half-life of the parent compound is 3-4 hours. After oral administration, approximately 50% is excreted in the feces and 42% by the kidneys, mainly as 5-hydroxylornoxicam. The half-life of 5-hydroxylornoxicam is approximately 9 hours after single or twice-daily parenteral administration. There is no evidence that the elimination rate changes with repeated dosing.

In elderly patients over 65 years of age, clearance is reduced by 30-40%. Apart from reduced clearance, there is no significant change in the kinetic profile of lornoxicam in elderly patients.

There is no significant change in the kinetic profile of lornoxicam in patients with renal or hepatic impairment, except for accumulation in patients with chronic liver disease after 7 days of treatment with daily doses of 12 and 16 mg.

Preclinical safety data

Preclinical data reveal no special hazard for humans based on standard studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.

Lornoxicam caused renal toxicity and gastrointestinal ulceration in single and repeated dose toxicity studies in several species.

In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

In rats, lornoxicam impairs fertility (effects on ovulation and implantation) and affects pregnancy and delivery. In rabbits and rats, lornoxicam caused premature closure of the ductus arteriosus due to cyclooxygenase inhibition.

Therapeutic indications

Short-term symptomatic treatment of acute mild to moderate pain in adults.

Posology and method of administration

Posology

This specific pharmaceutical form should only be used when rapid pain relief is required or if oral administration is not possible. Generally, treatment should consist of only one injection to initiate therapy.

For all patients, the appropriate dosing regimen should be based on individual response to treatment.

Undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms (see section Special warnings and precautions for use).

Pain

Recommended dose: 8 mg for intravenous (IV) or intramuscular (IM) injection. Some patients may require an additional 8 mg administered during the first 24 hours. The daily dose should not exceed 16 mg.

Special populations

Pediatric population

The use of lornoxicam is not recommended in children and adolescents (under 18 years of age) due to a lack of data on safety and efficacy.

Elderly

No special dose modification is required for patients over 65 years of age, except in cases of renal or hepatic impairment. Lornoxicam should be administered with caution, as gastrointestinal adverse effects are less well tolerated in this group (see section Special warnings and precautions for use).

Renal impairment

For patients with mild to moderate renal impairment, dose reduction should be considered (see section Special warnings and precautions for use). Lornoxicam is contraindicated in patients with severe renal impairment (see section Contraindications).

Hepatic impairment

For patients with moderate hepatic impairment, dose reduction should be considered (see section Special warnings and precautions for use). Lornoxicam is contraindicated in patients with severe hepatic impairment (see section Contraindications).

Method of administration

The route of administration is intravenous (IV) or intramuscular (IM) injection. When administered as an IV injection, the injection time should be at least 15 seconds, and for IM injection - at least 5 seconds.

After preparing the solution, the needle must be changed. For IM injection, a sufficiently long needle is required for deep intramuscular injection.

For further instructions on handling before use of the product, see section "Special precautions for disposal and other handling".

The medicinal product is intended for single use only.

Side effects

The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see Special warnings and precautions for use). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see Special warnings and precautions for use) have been reported following administration of NSAIDs. Less frequently, gastritis has been observed.

Approximately 20% of patients treated with lornoxicam can be expected to experience adverse reactions. The most frequent adverse effects of lornoxicam include nausea, dyspepsia, indigestion, abdominal pain, vomiting, and diarrhoea. In available studies, these symptoms generally occurred in less than 10% of patients.

Oedema, hypertension, and cardiac failure have been reported in association with NSAID treatment.

Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see Special warnings and precautions for use).

Exceptionally, occurrence of serious infectious complications of the skin and soft tissues during varicella.

The following lists adverse effects that generally occurred in more than 0.05% of the 6,417 patients treated in phase II, III and IV clinical trials.

The following convention is used for the classification of the frequency of an adverse drug reaction: very common (³1/10); common (³1/100, <1/10); uncommon (³1/1,000, <1/100); rare (³1/10,000, <1/1,000); very rare (<1/10,000); not known (frequency cannot be estimated from the available data).

Infections and infestations

Rare: pharyngitis.

Blood and lymphatic system disorders

Rare: ​​anemia, thrombocytopenia, leukopenia, prolonged bleeding time

Very rare: ​​ecchymosis. NSAIDs have been reported to cause potentially severe hematological disorders such as neutropenia, agranulocytosis, aplastic anemia, and hemolytic anemia as class effects.

Immune system disorders

Rare: hypersensitivity including anaphylactoid reactions and anaphylaxis.

Metabolism and nutrition disorders

Uncommon: ​​anorexia, weight changes.

Psychiatric disorders

Uncommon: ​​insomnia, depression.

Rare: confusion, nervousness, agitation.

Nervous system disorders

Common: mild and transient headache, dizziness.

Rare: somnolence, paraesthesia, dysgeusia, tremor, migraine.

Very rare: aseptic meningitis in patients with SLE and mixed connective tissue disease (see special warnings and precautions)

Eye disorders

Common: conjunctivitis.

Rare: visual disturbances.

Ear and labyrinth disorders

Uncommon: vertigo, tinnitus.

Cardiac disorders

Uncommon: ​​palpitations, tachycardia, oedema, heart failure (see special warnings and precautions).

Vascular disorders

Uncommon: ​​flushing, oedema.

Rare: hypertension, sudden feeling of heat, bleeding, hematoma.

Respiratory, thoracic and mediastinal disorders

Uncommon: ​​rhinitis.

Rare: ​​dyspnea, cough, bronchospasm.

Gastrointestinal disorders

Common: nausea, abdominal pain, dyspepsia, diarrhea, vomiting.

Uncommon: constipation, flatulence, eructation, dry mouth, gastritis, gastric ulcer, upper abdominal pain, duodenal ulcer, mouth ulceration.

Rare: melena, hematemesis, stomatitis, esophagitis, gastroesophageal reflux, dysphagia, aphthous stomatitis, glossitis, perforated peptic ulcer, gastrointestinal bleeding.

Hepatobiliary disorders

Uncommon: ​​elevated liver function tests, SGPT (ALT) or SGOT (AST).

Very rare: hepatotoxicity leading to, for example, liver failure, hepatitis, jaundice and cholestasis.

Skin and subcutaneous tissue disorders

Uncommon: ​​rash, pruritus, hyperhidrosis, erythematous rash, urticaria, angioneurotic oedema, alopecia.

Rare: dermatitis, eczema, purpura.

Very rare: ​​oedema and bullous reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Musculoskeletal and connective tissue disorders

Uncommon: ​​arthralgia.

Rare: bone pain, muscle spasms, myalgia.

Renal and urinary disorders

Rare: nocturia, micturition disorder, increase in blood urea nitrogen and creatinine levels.

Very rare: ​​Lornoxicam may cause acute renal failure in patients with pre-existing renal impairment who are dependent on renal prostaglandins to maintain renal blood flow (see Special warnings and precautions for use). As a class effect, nephrotoxicity in various forms, including nephritis and nephrotic syndrome, has been associated with NSAIDs.

General disorders and administration site conditions

Uncommon: malaise, facial oedema.

Rare: asthenia.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Contraindications

–  Hypersensitivity to lornoxicam or to any of the excipients listed in section List of excipients

–  Thrombocytopenia

–  Hypersensitivity (symptoms like asthma, rhinitis, angioedema or urticaria) to other NSAIDs, including acetylsalicylic acid

–  Severe heart failure

–  Gastrointestinal bleeding, cerebrovascular bleeding or other bleeding disorders

–  History of gastrointestinal bleeding or perforation related to previous NSAID therapy

–  Active or recurrent peptic ulcer/bleeding in history (two or more distinct episodes of proven ulceration or bleeding)

–  Severe hepatic impairment

–  Severe renal impairment (serum creatinine > 700 mmol/L)

–  Third trimester of pregnancy (see section Fertility, pregnancy and lactation)

Interaction with other medicinal products and other forms of interaction

Concomitant administration of lornoxicam and

–  Cimetidine: increased plasma concentration of lornoxicam, which may increase the risk of adverse effects of lornoxicam (no interaction has been demonstrated between lornoxicam and ranitidine, or lornoxicam and antacids).

–  Anticoagulants: NSAIDs may enhance the effects of anticoagulants, such as warfarin (see section Special warnings and precautions for use). Careful monitoring of INR should be carried out.

–  Phenprocoumon: Decreased effect of phenprocoumon treatment.

–  Heparin: NSAIDs increase the risk of bleeding and spinal or epidural hematoma when co-administered with heparin in the context of spinal or epidural anesthesia (see section Special warnings and precautions for use).

–  ACE inhibitors: The antihypertensive effect of the ACE inhibitor may be reduced.

–  Diuretics: Decreased diuretic and antihypertensive effect of loop diuretics, thiazide diuretics and potassium-sparing diuretics (increased risk of hyperkalemia and nephrotoxicity).

–  Beta-blockers: Decreased antihypertensive efficacy.

–  Angiotensin II receptor blockers: decreased antihypertensive efficacy.

–  Digoxin: decreased renal clearance of digoxin, which increases the risk of digoxin toxicity.

–  Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4).

–  Quinolone antibiotics (e.g., levofloxacin, ofloxacin): increased risk of convulsions.

–  Antiplatelet agents (e.g., clopidogrel): increased risk of gastrointestinal bleeding (see section Special warnings and precautions for use).

–  Other NSAIDs: increased risk of gastrointestinal bleeding or ulceration.

–  Methotrexate: Increased serum concentration of methotrexate. May cause increased toxicity. If concomitant therapy is required, careful monitoring should be performed.

–  Selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see section Special warnings and precautions).

–  Lithium: NSAIDs inhibit renal clearance of lithium, therefore serum lithium concentration may increase above toxicity limits. Therefore, serum lithium levels require monitoring, especially during initiation, adjustment, and discontinuation of treatment.

–  Cyclosporine: Increased serum concentration of cyclosporine. Cyclosporine nephrotoxicity may be enhanced by renal prostaglandin-mediated effects. Renal function monitoring is required during combined treatment.

–  Sulfonylureas (e.g., glibenclamide): Increased risk of hypoglycemia.

–  Known inducers and inhibitors of CYP2C9 isoenzymes: Lornoxicam (like other NSAIDs dependent on cytochrome P450 2C9 (CYP2C9 isoenzyme)) interacts with known inducers and inhibitors of CYP2C9 isoenzymes (see section "Pharmacokinetic properties", Biotransformation).

–  Tacrolimus: Increases the risk of nephrotoxicity due to decreased prostacyclin synthesis in the kidneys. Renal function should be monitored during combined treatment (see section Special warnings and precautions for use).

–  Pemetrexed: NSAIDs may reduce the renal clearance of pemetrexed, resulting in increased renal and gastrointestinal toxicity and myelosuppression.

Special warnings and precautions for use

Lornoxicam reduces platelet aggregation and prolongs bleeding time. Consequently, caution is required when used in patients with an increased tendency to bleed.

In the following disorders, lornoxicam should only be prescribed after a careful risk-benefit assessment:

–  Renal impairment: Lornoxicam should be administered with caution in patients with mild (serum creatinine 150-300 µmol/L) and moderate (serum creatinine 300-700 µmol/L) renal impairment due to the dependence of renal blood flow maintenance on renal prostaglandins (see section Posology and method of administration). If renal function deteriorates during treatment, lornoxicam treatment should be discontinued.

–  Renal function should be monitored in patients:

o   undergoing major surgery

o   with heart failure

o   receiving treatment with diuretics, receiving concomitant treatment with drugs that are suspected or known to cause renal damage (see section Interaction with other medicinal products and other forms of interaction).

–  Patients with blood coagulation disorders: careful clinical monitoring and evaluation of laboratory parameters (e.g., APTT) are recommended.

–  Hepatic impairment (e.g., liver cirrhosis): clinical monitoring and evaluation of laboratory parameters at regular intervals should be considered in patients with hepatic impairment, as accumulation of lornoxicam (increase in AUC) may occur after treatment with daily doses of 12-16 mg (see section Pharmacokinetic properties). In addition, hepatic impairment does not appear to affect the pharmacokinetic parameters of lornoxicam compared to healthy subjects.

–  In elderly patients over 65 years of age: monitoring of renal and hepatic function is recommended. Caution is advised in elderly postoperative patients.

Concomitant use of NSAIDs

Concomitant use of lornoxicam with NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided (see section Interaction with other medicinal products and other forms of interaction).

Minimization of undesirable effects 

Undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms (see section Posology and method of administration and gastrointestinal and cardiovascular risks below).

Gastrointestinal tract bleeding, ulceration and perforation

Gastrointestinal (GI) bleeding, ulceration and perforation: GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.

The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with bleeding or perforation (see section Contraindications), and in the elderly. In these patients,  treatment should be initiated at the lowest available dose (see section Posology and method of administration). Combination therapy with protective agents (e.g., misoprostol or proton pump inhibitors) should be considered for these patients, as well as for patients requiring concomitant low dose acetylsalicylic acid or other medicinal products likely to increase gastrointestinal risk (see below and section Interaction with other medicinal products and other forms of interaction). Clinical monitoring at regular intervals is recommended.

Patients with a history of GI toxicity, particularly the elderly, should be instructed to report any unusual abdominal symptoms (especially GI bleeding), particularly in the initial stages of treatment.

Caution should be exercised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section Interaction with other medicinal products and other forms of interaction).

When GI bleeding or ulceration occurs in patients receiving lornoxicam, the treatment should be withdrawn.

NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated (see section Undesirable effects).

Elderly

The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section Posology and method of administration).

Cardiovascular and cerebrovascular effects

Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.

Clinical trials and epidemiological data suggest that the use of some NSAIDs, particularly at high doses and in long-term treatment, may be associated with an increased risk of arterial thrombotic events (for example, myocardial infarction or stroke). There are insufficient data to exclude such a risk for lornoxicam.

Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with lornoxicam after careful consideration. Similar consideration should be given before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking).

Concurrent treatment with NSAIDs and heparin in the context of spinal or epidural anesthesia increases the risk of spinal/epidural hematoma (see section Interaction with other medicinal products and other forms of interaction).

Skin disorders

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have been reported very rarely in association with the use of NSAIDs (see section Undesirable effects). Patients appear to be at highest risk for these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Lornoxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Respiratory disorders

Caution is required in patients suffering from or with a history of bronchial asthma, as NSAIDs have been reported to cause bronchospasm in such patients.

Systemic lupus erythematosus and mixed connective tissue disease

Caution is required in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders, due to an increased risk of developing aseptic meningitis.

Nephrotoxicity

Concomitant treatment with NSAIDs and tacrolimus may increase the risk of nephrotoxicity due to reduced synthesis of prostacyclin in the kidneys. Therefore, careful monitoring of renal function should be performed in patients receiving combination therapy (see section Interaction with other medicinal products and other forms of interaction).

Laboratory abnormalities

As with most NSAIDs, occasional elevations of serum transaminases, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen and other laboratory abnormalities have been reported. If any such abnormality proves significant or persists, lornoxicam should be discontinued and appropriate investigations prescribed.

Fertility

The use of lornoxicam, like any medication that inhibits cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended for women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of lornoxicam should be considered (see section Fertility, pregnancy and lactation).

Chickenpox

In exceptional cases, chickenpox can be the cause of serious infectious complications of the skin and soft tissues.

To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Therefore, it is advisable to avoid the use of lornoxicam in case of chickenpox.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

Fertility, pregnancy and lactation

Pregnancy

Lornoxicam is contraindicated in the third trimester of pregnancy (see section Contraindications) and should not be used during the first and second trimesters of pregnancy and during delivery, as there are no clinical data on the use of the drug during pregnancy.

There are no adequate data on the use of lornoxicam in pregnant women. Animal studies have shown reproductive toxicity (see section Preclinical safety data).

Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and cardiac malformations after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality.

From the 20th week of pregnancy, the use of lornoxicam may cause oligohydramnios resulting from fetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation. In addition, there have been reports of ductus arteriosus constriction following treatment in the second trimester, most of which resolved after treatment cessation. Therefore, lornoxicam should not be given during the first and second trimesters of pregnancy unless clearly necessary. If lornoxicam is used by a woman attempting to conceive, or during the first and second trimesters of pregnancy, the dose should be kept as low and duration of treatment as short as possible. Antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered after exposure to lornoxicam for several days from gestational week 20 onward. Lornoxicam should be discontinued if oligohydramnios or ductus arteriosus constriction is found.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to:

–  cardiopulmonary toxicity (premature constriction/closure of the ductus arteriosus and pulmonary hypertension);

–  renal dysfunction (see above);

In the mother and the neonate, at the end of pregnancy:

-   possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses;

-   inhibition of uterine contractions resulting in delayed or prolonged labour.

Therefore, lornoxicam is contraindicated during the third trimester of pregnancy (see section Contraindications and Preclinical safety data).

Breast-feeding

There are no data on the excretion of lornoxicam in human breast milk. Lornoxicam is excreted in the milk of lactating rats in relatively high concentrations. Therefore, lornoxicam should not be used in breast-feeding women.

Fertility

The use of lornoxicam, like any medication that inhibits cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended for women attempting to conceive. In women who have difficulty conceiving or are undergoing investigation of infertility, withdrawal of lornoxicam should be considered.

Effects on ability to drive and use machines

Patients who experience dizziness and/or somnolence during treatment with lornoxicam should refrain from driving or operating machinery.

Overdose

At present, there is no experience with overdose to permit defining the consequences of an overdose or suggesting specific treatment. However, it is expected that the following symptoms may occur after an overdose of lornoxicam: nausea, vomiting, cerebral symptoms (dizziness, visual disturbances). Severe symptoms such as ataxia (progressing to coma and convulsions), liver and kidney damage, and potential coagulation disorders may also develop.

In case of actual or suspected overdose, the medicinal product should be withdrawn. Due to its short half-life, lornoxicam is rapidly excreted. Lornoxicam is not dialysable. No specific antidote is known to date. For example, gastrointestinal disorders can be treated with a prostaglandin analogue or ranitidine.

Nature of the container and composition

1 set contains:

Injection powder, 8 mg: amber glass vial, I hydrolytic class, closed with a grey bromobutyl rubber stopper and white plastic disc equipped aluminum cap.

Injection water, 2 ml: clear, I type glass ampoule with a break ring.

The medicinal product is available as a kit, which contains injection solution powder 10 vials and 10 ampoules of solvent for injection solution, which together are packed in a PVC foil protective tray.

Pack sizes: 10 kits. Not all pack sizes may be marketed.

Special precautions for storage

Do not store above 25°C . Store in the original package to protect from light

The solution for injection is prepared by dissolving the contents of one vial in water for injections, from the accompanying ampoule, immediately before use. The appearance of the product after reconstitution is a yellow, clear liquid.

If visible signs of deterioration are observed in the medicinal product, the product should not be used.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Shelf life

Unopened vial: 2 years.

Reconstituted solution: in-use chemical and physical stability has been demonstrated for 24 hours, at 25°C temperature.

From a microbiological point of view, if the method of reconstitution/dilution does not preclude the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use, are the responsibility of the user.

Dispensing conditions from pharmacies

Pharmaceutical product group II, issued with a form No. 3 prescription

Also, see: Lornado lyophilized 8mg 3 vials + solvent

Translated by AI